Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Date:1/14/2008

DETROIT, Jan. 14 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (Amex: CPD) announced today that the US Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Glipizide/Metformin Hydrochloride Tablets, 2.5/250 mg, 2.5/500 mg and 5/500 mg (Glipizide/Metformin HCl).

Glipizide/Metformin HCl is indicated as initial therapy, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes whose hyperglycemia cannot be satisfactorily managed with diet and exercise alone. It is also indicated as second-line therapy when diet, exercise, and initial treatment with a sulfonylurea or metformin do not result in adequate glycemic control in patients with type 2 diabetes. Our generic Glipizide/Metformin HCl is the bioequivalent to Metaglip(R), a registered trademark of Bristol-Myers Squibb Company. According to IMS Data, for the twelve months ended September 2007, Glipizide/Metformin HCl generic and brand products (Metaglip(R)) combined had annual sales of approximately $25 million.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to gain this approval from the FDA. Our focus continues to be working towards expanding our product line effectively, including products that are already available generically in the market that potentially can add measurable value."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to t
'/>"/>

SOURCE Caraco Pharmaceutical Laboratories, Ltd.,
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Daily Gossip reveals in its review that the Flat Belly ... loss tips. , The author of the new method ... to implement. Users don’t have to worry, as they will ... counting calories. , The Flat Belly Forever program was ... weeks weight loss program to help sufferers model the perfect ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... at 10 tips to help drug or alcohol addicts cope ... process, and one that former addicts and those who support ... Drug Rehabilitation’s CEO Per Wickstrom . , According ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... events experienced during deployment, returning National Guard soldiers ... if faced with civilian life setbacks, including job ... legal problemsall commonplace in military families. Results of ... School of Public Health are published online in ... , Alcohol abuse is a major concern for ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2
... Company (NYSE: PG ) announced net sales growth of ... Organic sales were up five,percent, delivering at the mid-point of ... led by strong growth in the Beauty, Fabric,Care & Home ... earnings,per share increased 12 percent to $1.03 for the quarter., ...
... /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... device company that develops, manufactures and markets ... it will be attending the,Credit Suisse Asian ... Location: Beijing, China, China Medical ...
... Melting Pot Restaurants join,St. Jude Children,s Research Hospital in ... - Dec. 31 to "give thanks for the healthy ... not.", "From the beginning, our involvement with St. ... said Kendra Sartor, vice president,of brand development for The ...
... growth, the global fluoroscopy and mobile C-arms market is forecast to ... form a large chunk of total market, particularly in the developed ... Asia-Pacific. , ... San Jose, CA (PRWEB) October 29, ...
... campaign against the threat of Coronary Heart Disease joined by Royle Family ... ... Tomlinson has warned British men against the threat of Coronary Heart Disease ... that he did not take his heart health seriously in the past ...
... 28 Today the ... responded to a request ... to hold an unnecessary,debate., ... letters, please visit:, http://www.noonprop8.com/downloads/FSchubert102808.pdf ...
Cached Medicine News:Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 2Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 3Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 4Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 5Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 6Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 7Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 8Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 9Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 10Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 11Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 12Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 13Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 14Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 15Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 16Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 17Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 2Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 3Health News:Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts 2Health News:Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts 3Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 2Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 3
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... System provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon Fiber Reinforced Polymer material emulates the ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Cage system is a carbon fiber reinforced ... and biologic functions of posterior lumbar interbody ... provides a device designed to meet the ... cancellous bone, the best possible bone for ...
... is highly adaptable and therefore suitable for ... to its extraordinary small outer diameter and ... of a simple but secure and reliable ... steering instruments around the corner. These characteristics ...
Medicine Products: